单位：[1]National CancerCenter/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing/CN[2]Zhejiang Cancer Hospital, Institute of Basic Medicine andCancer (IBMC), Chinese Academy of Sciences, Hangzhou/CN浙江省肿瘤医院[3]TongjiHospital, Tongji Medical University, Huazhong University of Science andTechnology, Wuhan/CN华中科技大学同济医学院附属同济医院[4]Shanghai Clinical Research Center forRadiation Oncology, Shanghai Key Laboratory of Radiation Oncology,Fudan University Shanghai Cancer Center, Shanghai Medical College,Fudan University, Shanghai/CN[5]Shanxi Cancer Hospital and theAffiliated Cancer Hospital of Shanxi Medical University, Taiyuan/CN[6]Harbin Medical University Cancer Hospital, Harbin/CN[7]The AffiliatedCancer Hospital of Zhengzhou University, Zhengzhou/CN河南省肿瘤医院[8]The AffiliatedCancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research, Nanjing/CN[9]Tianjin MedicalUniversity Cancer Institute and Hospital, National Clinical ResearchCenter for Cancer, Key Laboratory of Cancer Prevention and Therapy,Tianjin’s Clinical Research Center for Cancer, Tianjin/CN[10]NationalCancer Center/National Clinical Research Center for Cancer, CancerHospital, Chinese Academy of Medical Sciences and Peking Union MedicalCollege, Shenzhen/CN[11]The First Affiliated Hospital of The University ofScience and Technology of China (USTC), Division of Life Sciences andMedicine, University of Science and Technology of China, Hefei/CN[12]Xuzhou Cancer Hospital, Xuzhou/CN[13]Air Force Medical Center,Beijing/CN[14]First Hospital Of Lanzhou University, Lanzhou/CN[15]Shengli Oilfield Central Hospital, Dongying/CN[16]Sidney KimmelComprehensive Cancer Center, Johns Hopkins University School ofMedicine, Baltimore/MD/USA[17]State Key Laboratory of Oncology inSouth China, Sun Yat-sen University Cancer Center, Guangzhou/CN
第一作者单位：[1]National CancerCenter/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing/CN
推荐引用方式(GB/T 7714)：
Bi N.,Zhang T.,Hu X.,et al.Preliminary Safety and Treatment Data of A Phase 3 Trial: Hypofractionated vs Conventional Fractionated Concurrent Chemoradiation for LS-SCLC[J].JOURNAL OF THORACIC ONCOLOGY.2023,18(11):S166-S166.
APA：
Bi, N.,Zhang, T.,Hu, X.,Zhang, L.,Zhang, J....&Wang, L..(2023).Preliminary Safety and Treatment Data of A Phase 3 Trial: Hypofractionated vs Conventional Fractionated Concurrent Chemoradiation for LS-SCLC.JOURNAL OF THORACIC ONCOLOGY,18,(11)
MLA：
Bi, N.,et al."Preliminary Safety and Treatment Data of A Phase 3 Trial: Hypofractionated vs Conventional Fractionated Concurrent Chemoradiation for LS-SCLC".JOURNAL OF THORACIC ONCOLOGY 18..11(2023):S166-S166
医学